Bio-pharmaceutical developer Novavax (NVAX +4%) trades higher after winning a $1.3M contract from the U.S. Department of Homeland Security to develop a virus-like particle vaccine countermeasure to protect against foot-and-mouth disease.
Bio-pharmaceutical developer Novavax (NVAX +4%) trades higher after winning a $1.3M contract...
From other sites
at CNBC.com (Jan 15, 2015)
at CNBC.com (Jun 6, 2014)
at CNBC.com (Apr 23, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs